Review

Functional and cognitive impairment, social environment, frailty and adverse health outcomes in older patients with head and neck cancer, a systematic review

Floor J. van Deudekom a,⇑, Anouk S. Schimberg b, Marije H. Kallenberg a,c, Marije Slingerland d, Lily-Ann van der Velden b,e,1, Simon P. Mooijaart a,f,1

a Department of Gerontology and Geriatrics, Leiden University Medical Centre, The Netherlands
b Department of Otorhinolaryngology and Head and Neck Surgery, Leiden University Medical Centre, The Netherlands
c Department of Nephrology, Leiden University Medical Centre, Leiden, The Netherlands
d Department of Medical Oncology, Leiden University Medical Centre, The Netherlands
e Department of Head and Neck Surgery and Oncology, Netherlands Cancer Institute, Amsterdam, The Netherlands
f Institute for Evidence-based Medicine in Old Age (IEMO), Leiden, The Netherlands

Article info

Article history:
Received 5 August 2016
Received in revised form 24 October 2016
Accepted 24 November 2016
Available online 1 December 2016

Keywords:
Head and neck cancer
Functional impairment
Cognitive impairment
Social environment
Frailty
Systematic review
Mood

Abstract

Objectives: Older head and neck cancer patients are at increased risk for adverse health outcomes, but little is known about which geriatric assessment associates with poor outcome. The aim is to study the association of functional or cognitive impairment, social environment and frailty with adverse health outcomes in patients with head and neck cancer.

Methods: Four libraries were searched for studies reporting on an association of functional or cognitive impairment, social environment and frailty with adverse outcomes in head and neck cancer patients.

Results: Of 4158 identified citations, 31 articles were included. The mean age was >60 years in twelve studies (39%). Geriatric conditions were prevalent: between 40 and 50% of the included participants were functional impaired, around 50% had depressive symptoms, and around 40% did not have a partner. Functional impairment was assessed in 18 studies, two studies reported on a cognitive test, eight studies examined mood and social status was depicted by 14 studies. None of the included studies addressed frailty or objectively measured physical capacity such as hand grip strength, gait speed or balance tests. In 64% of the reported associations, a decline in functional or cognitive impairment, mood or social environment was associated with adverse outcomes.

Conclusion: Functional and cognitive impairment, depressive symptoms and social isolation are highly prevalent in head and neck cancer patients and associate with high risk of adverse health outcomes. In the future, these measurements may guide decision-making and customize treatments, but more research is needed to further improve and firmly establish clinical usability.

Introduction

With population ageing there will be an increasing number of older patients with cancer. This trend can also be observed in the patient population presenting with head and neck cancer. In the USA, it is estimated that between 2010 and 2030 the incidence of oral cavity and pharyngeal cancer in people aged 65 years and over will approximately increase from 19,000 patients in 2010 to 31,000 patients in 2030. This would be an increase with more than 60% [1]. Older patients are very heterogeneous with respect to functional capacity, cognitive functioning, mobility and frailty, therefore it remains challenging to identify older patients who are at highest risk for adverse health outcomes such as delirium, side-effects, prolonged length of hospital stay, reduced quality of life or mortality. Besides, head and neck cancer patients have a severe prognosis with an estimation of 50% after 5 years with large variations across tumor sites [2,3]. However, the prognostic value of functional capacity, cognitive functioning, mobility and frailty to assist clinical decision making in older head and neck cancer patients has not been systematically evaluated.

⇑Corresponding author at: Department of Gerontology and Geriatrics, Leiden University Medical Centre, PO Box 9600, 2300 RC Leiden, The Netherlands.
E-mail address: F.J.A.van_Deudekom@lumc.nl (F.J. van Deudekom).
1 L.A. van der Velden and S.P. Mooijaart should be considered joint last authors of this work.

http://dx.doi.org/10.1016/j.oraloncology.2016.11.013
1368-8375/© 2016 The Author(s). Published by Elsevier Ltd.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Head and neck cancer patients have a high prevalence of previous excessive alcohol drinking and smoking [4–6] putting this group at high risk for deterioration in functional [7] and cognitive decline [6,8]. Previously identified risk predictors in older patients with head and neck cancer are the burden of comorbidities [9] and nutritional status [10,11]. A recent review concluded that there was strong evidence for a positive association of pre-treatment physical functioning with survival and change in global quality of life [12]. But, with regard to other HRQoL domains (emotional, cognitive and social functioning) there was insufficient evidence. In other fields of geriatric medicine the value of measures of functional capacity, cognitive functioning, the role of social environment and frailty [13–15], has been firmly established, but these have not been reviewed for older patients with head and neck cancer.

Therefore, the aim of this present systematic review is to study the association of functional or cognitive impairment, social environment and frailty with adverse health outcomes in patients with head and neck cancer.

Methods

Search strategy

We aimed to identify original longitudinal studies in head and neck cancer patients in which the association between a measurement of functional and cognitive impairment, social environment or frailty prior to treatment initiation and adverse health outcome after follow-up was examined. A head and neck tumor was defined as cancers in the sinonasal, nasopharyngeal, oral, oropharyngeal, hypopharyngeal, supraglottic, glottis, subglottic regions or laryngeal cancer. Since the etiologic, risk factors and treatment for skin tumors and thyroid cancer are different from mucosal tumors, skin tumors and thyroid cancers were not included in the search. As baseline measurement we assessed the presence of functional impairment (including assessment of functional performance, mobility, and objectively measured physical capacity such as hand grip strength, gait speed or balance tests), cognitive impairment (including assessment of cognition, dementia diagnosis, and mood or depression), social environment (living situation, social support and marital status) and frailty (the use of a frailty index or instrument such as Fried Frailty Phenotype or the Groningen Frailty Indicator). We assessed adverse health outcomes as mortality, functional or cognitive decline, adverse events during or after treatment (such as side-effects or delirium), prolonged length of hospital stay (LOS) and health related quality of life (HRQoL) of global quality of life (QoL) after follow-up.

On April 28th 2016, we searched four electronic bibliographic databases (PubMed, Embase, Web of Science and the Cochrane Library) using synonyms of head and neck cancer, combined with synonyms of the different domains of geriatric assessment. No limits in age were applied. For full Medline search, see Supplemental Material A.

Article selection

The eligibility of all studies identified by the search was independently evaluated by two of the authors (F.v.D. and A.S.). Of any article that seemed potentially relevant based on title and abstract, full text was retrieved and screened. Studies were included if the full text contained original data reporting on an association between any geriatric measure at baseline and outcome after follow-up in head and neck cancer patients in a longitudinal study design. In case of disagreement between the two authors (F.v.D., A.S.), consensus was reached after discussion with two other co-authors (S.P.M., L.vd.V.). The reference list of the included publications was used for cross-referencing to ensure we identified all relevant articles.

Data extraction and quality assessment

Items extracted from each study included: publication data (author, year), study design and setting, patient characteristics (sample size, mean age, treatment modality), tumor type and tumor site measurement of functional or cognitive impairment, social environment or frailty, follow up duration, outcome measure and results of the association functional and cognitive impairment, social environment and frailty with adverse health outcome. Treatment modality can include therapy with a curative intent such as surgery, radiation therapy, chemoradiation (or as a combination) or with no curative intent such as chemotherapy, and also no treatment with palliative intent was taken into account as a treatment modality. To assess the methodological quality and risk of bias of the included studies, we adapted the Newcastle-Ottawa scale [16] to the purpose of this review (Supplemental Material B). In case of disagreement between the two authors (F.v.D., A.S.) with regards to data extraction or quality assessment, consensus was reached after discussion with the other two co-authors (S.P.M., L.vd.V.).

Data presentation

Study characteristics are tabulated per individual study. Accumulated descriptives of the selected studies are presented by calculating the proportion of studies reporting on measurement of functional or cognitive impairment, social environment or frailty, endpoints or treatment modalities. Sample size aggregate of the included studies is expressed as median- and interquartile range (IQR), calculated with SPSS software version 20. Main findings with respect to the association of measurement of functional or cognitive impairment, social environment or frailty with outcome are tabulated. In case the hazard ratios (HR), odds ratios (OR) and relative risk (RR) are at least adjusted for age in the multivariate analysis this is mentioned as aHR, aOR and aRR. If studies are adjusted for other factors than age, this is reported in the abbreviations.

Results

Search results and study selection

The database searches identified 4158 unique citations (Fig. 1). After the initial screening of title and abstract, 106 articles were considered potentially eligible. After full-text review, another 76 were excluded; the remaining 30 articles were included. Cross referencing yielded one additional relevant article, which resulted in a total of 31 studies that were included in the present review.

Study characteristics

Table 1 shows an overview of the study characteristics of the 31 included studies. The median sample size of all 31 studies included was 306 (IQR 124-600) and the mean age was over 60 years in twelve studies (39%). Twenty-one studies (68%) were conducted in Europe, the United States or Canada. Most studies consisted of head and neck cancer patients with various cancer types and locations combined, six studies included patients with a specific kind of tumor, five studies had specific inclusion criteria such as stage III/IV or (locally) advanced cancer and six studies included only one treatment modality. Only three studies focused exclusively on older patients and included age ≥70 years in their study population [17–19]. Several studies used specific exclusion criteria: four
excluded patients with cognitive impairment, five excluded specific cut off for age, such as excluding aged over 70, 75 or 80 years, some functional impairment (n = 3) or patients with no curative intent (n = 8).

Table 2 shows an overview of the associations of measures of functional or cognitive impairment, social environment and frailty with adverse health outcomes after follow up. The thirty-one studies reported on a total of 45 associations. Functional impairment was assessed in 18 studies, there were two studies reporting on a cognitive test, eight studies examined depressive symptoms and social status was studied in 14 studies. None of the studies addressed frailty or objectively measured physical capacity (such as hand grip strength, gait speed or balance tests). Survival (overall, total or disease specific survival) was the main outcome of interest in 21 studies (68%), the remaining studies assessed quality of life (global or health related, 19%), side effects (7%), the development of post-treatment delirium (7%) or prolonged length of stay in the hospital (7%). No studies were found reporting on cognitive or functional decline after treatment for head and neck cancer. Of the 45 reported associations, twenty-nine times (64%) a decline in functional or cognitive performance, mood or social environment was associated with an increased risk of one of the adverse outcomes (Fig. 2).

Functional impairment

Functional performance was assessed in 18 studies, mostly using the Eastern Cooperative Oncology Group Scale (ECOG-scale, 6 studies) [19–24], or the Karnofsky Performance Score (KPS, 8 studies) [17,18,25–30]. Functional impairment was prevalent in most studies. For instance, the largest study of Siddiqui et al., included 1093 patients and 517 (47%) had a KPS between 60 and 80, indicating patients were not able to work or need some help with daily care. Functional impairment was associated with increased risk of adverse outcomes in 12 out of 18 studies (67%). Functional performance was found to be associated with (overall) survival in 9 out of 12 studies (75%) [18,20,21,23,25,27,29–31]. Siddiqui et al. and found that KPS (90–100 vs 60–80) was an independent prognostic factor for overall survival (aHR 1.51 (95% CI 1.27–1.79)).

Cognitive impairment

There were only two articles that reported on the association between cognitive status and adverse health outcome. Shah et al. reported a prevalence of cognitive impairment of 5%, defining pre-existing cognitive impairment as any history or physical findings of stroke, transient ischemic attack or dementia [32]. The outcome measured was the development of a postoperative delirium, and 11 out of 39 patients with cognitive impairment developed a postoperative delirium (28%). Pre-existing cognitive impairment was significant correlated with a postoperative delirium (aHR 3.83 (95% CI 1.70–8.63)). Weed et al. measured cognitive function using the Folstein Mini-Mental State questionnaire (MMS) [34]. In this study 24 out of 138 patients (17%) developed a postoperative delirium, and these 24 patients had a mean MMS-score of 26.3.

Fig. 1. Flowchart.
| Publication | Patients | Study population | Exclusion criteria | Treatment modality |
|-------------|----------|------------------|-------------------|--------------------|
| Aarstad [39] | 2005 | 79 | SCC (maxilla, oral cavity, pharynx and larynx) | Not able to answer questions, aged >80, KPS <75, female | S, C, RTx or combination |
| Barber [38] | 2015 | 71 | Mucosal squamous cell carcinoma, salivary gland tumors and skin cancer | Pre-existing psychiatric history, not able to read or complete questionnaires, not able to give consent, not willing to complete follow-up | S, C |
| Borggreveny [46] | 2007 | 80 | Advanced SCC of the oral cavity or oropharynx | >75 year, cognitive impairment, not speaking Dutch | S with or without RTx |
| Epstein [48] | 2005 | 573 | Oropharyngeal cancer | No exclusion criteria available | NA |
| Fang [25] | 2004 | 102 | Stage III or IV head and neck cancer of the oral cavity, oropharynx, hypopharynx or larynx | Recurrent malignancies, synchronous malignancies, not able to complete QOL questionnaire | RTx with or without C |
| Gerude [17] | 2014 | 67 | SCC of upper aerodigestive tract | <74 year, unable to walk, unable to answer questions due to hearing, cognitive or speech deficits, impossibility anthropometric measurements | S |
| de Graeff [26] | 2001 | 208 | SCC of the oral cavity, oropharynx, hypopharynx or larynx | ≥80 year, recurrent malignancies, synchronous malignancies, cognitive impairment, not speaking Dutch, no curative intent | S, RTx or combination |
| Hall [20] | 2009 | 856 | SCC of the hypopharynx | No exclusion criteria available | S, RTx, C or combination |
| Hammerlid [35] | 2001 | 232 | Primary head and neck cancer (larynx, oral cavity, pharyngeal and other) | Not able to answer question due to cognitive impairment, mental disturbance or severe disease | S, RTx, CRTx or combination |
| Howren [36] | 2010 | 306 | Upper aerodigestive tract carcinoma (oral cavity, pharynx, larynx or other) | No exclusion criteria available | S, RTx or combination |
| Howren [47] | 2013 | 364 | Upper aerodigestive tract carcinoma (oral cavity, pharynx, larynx or other) | No exclusion criteria available | S, RTx or combination |
| Hsieh [21] | 2011 | 151 | SCC of the head and neck (oral, oropharynx, hypopharynx and larynx) | Nasopharyngeal cancer, medical conditions associated with leucocytosis and thrombocytosis, anaemia, metastatic cancer, non-head and neck SCC | NA |
| Karvonen [40] | 2008 | 495 | Head and neck cancer of the upper aerodigestive tract | Pregnancy, <18 years, not speaking English, recurrent tumor | S, RTx, C or combination |
| Kim [41] | 2015 | 241 | SCC of the oral cavity, oropharynx, larynx or hypopharynx | No curative intent, distant metastasis, recurrent tumor, aged <18 or >80 years | S, RTx or combination |
| Konski [27] | 2003 | 1073 | Locally advanced SCC (oral cavity, oropharynx, hypopharynx and supraglottic) of head and neck | No exclusion criteria available | RTx |
| Lotfi [28] | 2008 | 258 | Head and neck malignant neoplasm (mouth/lip/submandibular gland, oropharynx, larynx, hypopharynx) | No curative intent | S |
| Mell [22] | 2010 | 479 | Stage III-IV carcinoma (opharynx, larynx, hypopharynx, oral cavity, nasopharynx and other) of the head and neck | No exclusion criteria available | CRTx, C or S |
| Oska [42] | 2010 | 80 | Advanced SCC of the oral cavity or oropharynx | ≥75 year, serious cognitive impairment, not speaking Dutch | S with or without RTx |
| Orthus [45] | 2013 | 106 | SCC (laryngeal, oral cavity or oropharyngeal) of the head and neck | ≥78 year, cognitive impairment, no curative intent | S, C, or RTx |
| Pedruzzi [31] | 2008 | 361 | Primary SCC of the oropharynx | Distant metastasis | RTx with or without C |
| Ronis [37] | 2008 | 316 | SCC (oral cavity, pharynx, larynx, oropharynx, hypopharynx and nasopharynx) | Pregnancy, <18 years, not speaking English or mentally unstable | S, C, or RTx |
| Sadat [29] | 2012 | 169 | SCC (oral cavity, oropharynx, hypopharynx, and larynx) of the head and neck | Operable SCC | RTx or CRTx |
| Sanabria [18] | 2007 | 310 | Head and neck cancer (larynx, oral cavity, oropharynx and hypopharynx) | <70 year, no curative intent, distant metastasis, recurrent disease, surgery for thyroid cancer, skin cancer or melanoma, orbit tumors | RTx or combination |
| Shah [32] | 2012 | 774 | SCC of the head and neck | No exclusion criteria available | S |
| Siddiqui [30] | 2008 | 1093 | Several different cancers in two cohort-studies | No exclusion criteria available | RTx, C, S |
| Sze [19] | 2012 | 990 | Nasopharyngeal carcinoma | Palliative treatment, disseminated disease | RTx with or without C |
In this small sample size, there was no association reported of cognitive status measured by the Folstein Mini-Mental State questionnaire with the development of postoperative delirium.

Eight studies examined depression by using five different types of inventories using different scales. The study of Ronis et al., assessed depression by using the GDS-SF and 156 of 316 patients (49%) had significant depressive symptoms at baseline, and about the same prevalence was found in other studies. Five out of eight studies (62.5%) found a significant association of depression with an increased risk of one of the adverse health outcomes. In four studies assessing depressive symptoms was found that depressive symptoms at baseline were associated with lower global/health related quality of life after follow-up [35–38]. Depressive symptoms at baseline were a significant predictor of a negative change in HRQoL one year after diagnosis (adjusted for age \( p < 0.05 \), no estimation reported). The association of mood/depression and survival as outcome is inconsistent. One study [39] found that depression, measured by Beck Depression Inventory (BDI), at baseline predicts overall survival (aHR 1.13; \( p = 0.03 \)) and disease specific survival (aHR 1.19; \( p < 0.001 \)). On the other hand Karvonen-Gutierrez et al. measured depression by the Geriatric Depression Scale Short Form (GDS-SF) and found that this was no significant prognostic factor for overall survival (HR 1.30 (95% CI 0.98–1.73)) [40] and also Kim et al. found that pre-treatment depression was not significant predictive for three-year overall survival (aHR 1.52 (95% CI 0.82–2.81)) [41].

Social environment

Fourteen studies examined social environment and this was mostly assessed by marital status (34%) and living situation (10%), one study used Social Provision Scale (SPS). Around 35% of the participants did not have a (married) partner. Ten out of fourteen studies (71%) found an association of social environment with one of the outcomes. Six studies found that marital status (not married or not having a partner) was associated with a worse overall survival [26,30,40,42–44] and two studies did not find an association [25,45]. The quality of life after 3, 6 or 12 months was lower in patients who did not have a partner compared to patients who did have a partner [46,47]. There was only one study assessing the living situation with overall survival, this study found that patients living dependently had a higher risk for a reduced overall survival (aRR 2.33, \( p < 0.001 \)) and disease specific survival (aRR2.16, \( p < 0.001 \)) [48].

Quality assessment

The overall study quality assessed by the modified Newcastle-Ottowa scale was moderate (Table 3). Overall there were some concerns regarding the validity of the selection, the determination of outcome or reporting of the duration of follow up. The greatest concern with a majority of the studies was the representativeness of the study population, as 14 studies (48%) examined the association between a geriatric measure at baseline with outcome in a selected population in which only one kind of tumor, one kind of treatment modality or treatment intent was used. Furthermore, in several studies a risk of selection bias persisted because of various reasons: excluding older patients, cognitive impaired patients or with a restriction on the functional performance [17,26,27,30,35,37,39,41,42,45,46].

Discussion

In the present systematic review, we identified 31 articles reporting on the association of functional or cognitive impairment, social environment or frailty with adverse outcomes in patients with head- and neck cancer. There were three main findings: first, the decline in functional performance, depressive symptoms and decline in social environment were prevalent. Second, the majority of the studies reported a statistically significant association of impairment in functional and cognitive performance, mood or social environment with a higher risk of adverse outcome. Third, cognitive function was only assessed in two studies and frailty and objectively measured physical capacity, were not assessed at all in patients with head and neck cancer.

Impairment in functional performance, depression and social environment were highly prevalent, which emphasizes that the head and neck cancer patients are a very vulnerable patient group. Possibly, the observed associations in the present review are underestimated due to the relatively young population in the studies compared to the average population in the clinic, with only twelve studies (39%) reaching a mean age of 60 years and older.
Table 2
Association of functional and cognitive impairment, social environment and frailty with adverse health outcomes.

| Study       | Author | No. of patients | Geriatric measure and measured method | Outcome | Association |
|-------------|--------|-----------------|----------------------------------------|---------|-------------|
| Aarstad     | [39]   | 79              | Depression measured by (BDI)          | Total and disease specific survival, quality of life | Depression at baseline associated with worse overall survival (aHR 1.13 per increase in depression level p < 0.03) and disease specific survival (aHR 1.19; p < 0.001) No correlation between depression at diagnosis en QOL at follow-up (in subset of n = 27) |
| Barber      | [38]   | 71              | Depression measured by Quick Inventory of Depressive Symptomatology Self-Report (QIDS-SR) | FACT-NH-score, LOS, overall survival | Moderate-Severe depressive symptoms (QIDS-SR score 11–27) is a significant predictor of worse postoperative FACT-NH scores (aHR 5.66, p < 0.03), and a prolonged length of stay (p = 0.02) in comparison to normal-mild depressive symptoms. The overall survival was significantly worse in the moderate-severe group |
| Borggreven  | [46]   | 80              | Social environment depicted by marital status | Global quality of life | Not having a partner was significant associated with lower global QOL after six months (no estimate reported; p = 0.017), but not after 12 months (no estimate or p-value reported) |
| Epstein     | [48]   | 573             | Social environment depicted by living situation | Overall and disease free survival | Living in a long-term care facility associate with a significantly reduced overall (aHR 2.33 p < 0.001) and disease specific survival (aHR2.16, p < 0.001) when compared to independently-living |
| Fang        | [25]   | 102             | Social environment depicted by marital status, Functional capacity measured by KPS | Survival | Marital status is no predictor for overall survival (p = 0.095). KPS (=<80 vs >80) was an independent prognostic factor for survival (HR#2.03 (95% CI 1.27–3.24)) |
| Gerude      | [17]   | 67              | Functional capacity measured by ADL (Katz), IADL (Lawton-Brody) and KPS | Postoperative complications, (LOS) | IADL dependence (score >18) was significantly associated with postoperative complications (RR 2.19 (95% CI 1.21–3.94), p = 0.005) and a prolonged length of stay (RR 1.97 (95% CI 1.07–3.61) p = 0.02) There was no association of ADL or the KPS with postoperative complications or a prolonged length of stay |
| de Graeff   | [26]   | 208             | Social environment depicted by marital status, Functional capacity measured by KPS, Depression measured by CES-D, | Survival, time to event (=progression or death) | Marital status (unmarried) was significantly related to survival (RR 1.82 (95% CI 1.03–3.23)), compared to married status. CES-D and KPS were both no prognostic factor for survival or time to event |
| Hall        | [20]   | 856             | Functional capacity measured by the ECOG-scale | Overall and disease specific survival | ECOG-score was an independent predictor for overall (aHR 1.24 (95% CI 1.12–1.38)) and disease specific survival (aHR 1.26 (95% CI 1.10–1.43)) |
| Hammerlid   | [35]   | 232             | Depression measured by HADS | Global quality of life | Depression at diagnosis was an independent predictor for global QOL after 3 years (adjusted for age, p < 0.05, no estimate reported) |
| Howren      | [36]   | 306             | Depression measured by BDI | Health related quality of life | Depressive symptoms at time of diagnosis, negatively affect HRQOL over time |
| Howren      | [47]   | 364             | Social environment measured by the (SPS) | Global and head and neck specific HRQOL | Greater perceived support present at diagnosis significantly predicted more favourable global and head and neck cancer specific HRQOL (on subdomains speech, eating, aesthetics, social disruption) at 3 and 12 months, adjusted for age |
| Hsieh       | [21]   | 151             | Functional capacity measured by the ECOG-scale | Overall survival | ECOG performance status (0–1 vs ≥2) had a significant adverse impact on survival (aHR 5.203 (95% CI 2.257–11.993)) |
| Karvonnen   | [40]   | 495             | Depression measured by the GDS-SF, Social environment depicted by marital status, | Survival | Depressive symptoms were no prognostic factor for survival (HR 1.30 (95% CI 0.98–1.73)); Marital status (married) was significantly associated with survival (aHR 0.62 (95% CI 0.47–0.83)) |
| Kim         | [41]   | 241             | Depression measured by de BDI-II, a revised form of the BDI | Overall survival | Pretreatment depression was not significantly predictive for 3-year overall survival (aHR 1.52 (95% CI 0.82–2.81)) |
| Konski      | [27]   | 1073            | Functional capacity measured by KPS | Overall survival | KPS (90–100 vs 60–80) was an independent prognostic factor for overall survival (HR 1.90 p < 0.0001) |
| Lofli       | [28]   | 258             | Functional capacity measured by KPS | Surgical-site infection | There was no association with the risk of surgical-site infection and the KPS (p = 0.489) |
| Mell        | [22]   | 479             | Functional capacity measured by ECOG-scale | Competing mortality | Univariate analysis ECOG performance status (1–2) was significantly associated with mortality (HR 1.57 (95% CI 1.05–2.36)). Multivariate analysis showed no association |
| Oskam       | [42]   | 80              | Social environment depicted by marital status, | Overall and disease specific survival | Marital status (partner vs no partner) was predictive for disease specific survival (aHR 3.10 (95% CI 1.36–7.06)) and overall survival (no estimate reported) |
| Osthus      | [45]   | 106             | Social environment depicted by marital status, | Overall survival | Marital status (married vs other) was no prognostic factor for survival (aHR 0.68 (95% CI 0.34–1.35)) |
| Pedruzzi    | [31]   | 361             | Functional capacity measured by Zubrod-scale | Death | Zubrod-scale scores of 2 and 3 were independent prognostic factors risk of death(aHR 1.49 (95% CI 1.1–2.0) and aHR 1.94 (95% CI 1.2–3.3)) |
| Ronis       | [37]   | 316             | Depression measured by GDS-SF, Social environment depicted by marital status | Health related quality of life with SF-36 and HNQoL | Depressive symptoms at baseline is a significant predictor of change HRQOL one year after diagnosis, across various domains of SF-36 and HNQoL (p < 0.05), adjusted for age Marital status is not a predictive factor |
According to the Surveillance, Epidemiology, and End Results database, approximately 47% of all patients diagnosed with head and neck cancer (HNC) in the U.S. between 1973 and 2013 were 65 years and older [49]. It is not surprising that we find limited number of older patients in these studies. A review in 2012 showed that only 7% of all randomized clinical trials are specially designed for older adults [50]. It is known over various fields in medicine that older patients are underrepresented in clinical studies as a result of excluding individuals over a certain age or with a high burden of morbidities [50,51]. As a consequence, subjects enrolled in clinical trials, even those in the oldest cohort, often do not represent older patients in the general population [49,52]. Based on the results of the studies included in our review, we cannot determine which individual patient would experience adverse health outcomes and therefore the external validity of the individual studies is limited. The limited external validity is caused by the heterogeneous population, investigating a wide range of head and neck cancer types and treatment modalities and regimes, inclusion criteria, number of included patients, used geriatric assessment, age groups and outcome measurements.

Despite the heterogeneity of the studies and the low numbers of studies studying older patients it is the majority of included studies reported a significant association of functional impairment and social environment and some on cognitive impairment with adverse outcomes. These associations also have been shown in other oncology patients [54–56] and in community dwelling older people [14,57]. In general oncology, geriatric assessments are frequently used to guide treatment decision-making. General oncologists often assess functional capacity by assigning KPS and ECOG-score, and both assessments are independent prognostic factors for outcomes [58,59]. In (oncological) surgery cognitive impairment is a well-known risk factor for postoperative complications such as delirium and mortality [60–62]. In two recent meta-analyses depression diagnosis and higher levels of depressive symptoms in patients with different kind of cancers predicted elevated mortality [63,64]. Social isolation has been linked to an increased risk of mortality in geriatric and oncology literature [65,66]. This could be explained by the intensive treatment program for (head and neck) cancer, the chance of success of the intensive treatment is highest when there is a good social support. Although we cannot rule out publication bias with negative associations not being published, our findings are in line with the literature describing associations of impairments with adverse outcome. Most of the studies identified in the present systematic review, found an association with social status, depicted by marital status, and a worse overall survival.

Multiple promising geriatric assessments, such as various frailty indices and objectively measured physical capacity were not

---

**Table 2 (continued)**

| Study | No. of patients | Geriatric measure and measured method | Outcome | Association |
|-------|-----------------|---------------------------------------|---------|-------------|
| Sadat [29] | 169 | Functional capacity measured by KPS and ECOG-scale | Overall survival | KPS (≤70), and ECOG (≥2) were an independent prognostic factor for overall survival (aHR 1.51 (95% CI 0.97–2.35)) |
| Sanabria [18] | 310 | Functional capacity measured by KPS | Overall and cancer specific survival | KPS (≤80) was an independent prognostic factor for overall and cancer specific survival (aHR 2.0 (95% CI 1.40–2.87) and aHR 2.28 (95% CI 1.43–3.64)) |
| Shah [32] | 774 | Functional capacity measured by Specific Activity Scale (SAS) Social environment depicted by living situation Cognitive impairment as any history or physical findings of a stroke, TIA or dementia | Delirium yes/no | There was no significant correlation with SAS (HR 2.43 (95% CI 0.78–7.63)) or living situation (HR 1.18 (95% CI 0.69–2.01)) and the development of postoperative delirium Cognitive impairment was significantly correlated with a postoperative delirium (aHR 3.83 (95% CI 1.70–8.63)) |
| Siddiqui [30] | 1093 | Functional capacity measured by KPS Social environment depicted by marital status | Overall survival | KPS (60–80 vs 90–100, with aHR 1.507 (95% CI 1.268–1.791)) and marital status (married vs without partner with aHR 1.235 (95% CI 1.218–1.747)) were independent prognostic factor for overall survival |
| Sze [19] | 990 | Functional capacity measured by ECOG-scale | Overall and cancer specific survival | ECOG performance status (2–3 vs 0–1) was not a prognostic factor for overall (aHR 1.01 (95% CI 0.55–1.84)) or cancer specific survival (aHR 0.85 (95% CI 0.28–2.54)) |
| Tarstitano [43] | 124 | Social environment depicted by marital status | Overall survival | Having a partner was predictive for survival (no estimate or p-value reported) |
| Urbali [23] | 704 | Functional capacity measured by ECOG-scale | Overall survival and progression free survival | ECOG performance status (0–1 vs 2) had a significant effect on overall survival (aHR 0.56 (95% CI 0.42–0.75)) and progression free survival (aHR 0.71 (0.53–0.93)) |
| Wang [24] | 600 | Functional capacity measured by ECOG-scale | Overall and cancer specific survival | ECOG performance status was associated with borderline statistical significance (aHR 2.89 (95% CI 1.00–8.35)) with overall survival but not with cancer specific survival (aHR 0.86 (95% CI 0.11–6.48)) |
| Weed [34] | 138 | Cognitive status measured by MMS-questionnaire Functional capacity measured by SAS Social environment depicted by living situation | Delirium yes/no | Patient living alone developed significantly more frequent a postoperative delirium (no estimate reported, p = 0.005). Cognitive status and functional capacity had no effect |
| Wong [44] | 1010 | Social environment depicted by marital status | Overall survival | Marital status (married vs unmarried) had a significant difference in overall survival (aHR 1.528, p = 0.008) |

aHR, aRR, aOR = this is the adjusted values at least for age.

1 Both studies used the same cohort.

2 Studies conducted partly on same trial, Siddiqui et al. used partly the same patients (n = 689) as Konski et al.

3 Multivariate model contained: AJCC stage (IV vs III), N-status (N2-3 vs N0-1), KPS (<80 vs ≥80).

4 Multivariate model contained: race, educational level, TN-classification, KPS, site. Stratified by treatment.
assessed in patients with head and neck cancer. Objective geriatric measurements, such as gait speed, handgrip strength or Timed Up to GO Test (TUGT) can be useful geriatric screenings tools for the physician to risk stratify patients. Several studies examining the relation between physical capacity and outcomes as mortality or disability, found an association both in general and in oncological patient populations [67–70]. Frailty is associated with adverse health outcomes in surgical patients [61] as well in community dwelling older adults [14]. In addition, in a recent review in older cancer patients, frailty is associated with an increased risk of chemotherapy intolerance, postoperative complications and mortality [71]. In conclusion, both objective geriatric measurements and frailty are predictive of poor outcomes in general oncology, (oncologic) surgical patients, as well as community dwelling older adults. However, in older head and neck cancer patients evidence of physical capacity and frailty and its associations with adverse health outcomes is lacking.

A limitation of our study was that, due to heterogeneity among the included studies, especially with respect to the geriatric measure that was used, the reported measure of association (HR, OR, and relative risk), outcome measures, and covariate adjustments, made it impossible to compare outcomes of studies in a meta-analysis or to make a proper sub group analysis. Secondly, interpretation of the results may be hampered by possible publication bias, as negative associations in multivariate analyses may not have been reported in the studies. Strengths of this review include the systematic search we performed in several databases, assessing all potential relevant associations of functional and cognitive impairment, social environment and frailty with adverse health outcomes in head and neck cancer patients. Furthermore, quality assessment of the studies was undertaken to identify potential factors hampering external validity.

Our findings implicate that apart from specialists in head and neck oncology (such as head and neck surgeons and oncologists) the older head and neck cancer patient could benefit from an even more multidisciplinary approach. This could be implemented for instance by including a geriatrician in the multidisciplinary team in both the pre- and post-operative phase.

![Fig. 2. Graphic representation of association of functional or cognitive impairment and social environment with adverse health outcomes in patients with head and neck cancer. No studies reported the association between frailty and adverse health outcomes.](image)

| Publication   | Selection | Outcome | Quality assessment |
|---------------|-----------|---------|--------------------|
| First author  | publication year | Representativeness of the exposed cohort | Ascertainment of exposure (geriatric measure) | Assessment of outcome | Sufficient duration of follow-up | Adequacy of follow-up |
| Aarstad 2005  | --        | +       | +                  | +                  | +                  | ?                   |
| Barber 2015   | +         | +       | +                  | +                  | +                  | +                   |
| Borggreven 2007 | +/-       | +       | +                  | +                  | +                  | +                   |
| Epstein 2005  | --        | +       | +                  | +                  | +                  | ?                   |
| Fang 2004     | +/-       | +       | +                  | +                  | ?                  | +                   |
| Gerude 2011   | --        | +       | +                  | +                  | +                  | ?                   |
| de Graeff 2001 | +/-       | +       | +                  | +                  | +                  | +                   |
| Hall 2009     | +/-       | +       | +                  | +                  | +                  | +                   |
| Hammerlid 2001 | +         | +       | +                  | +                  | +                  | ?                   |
| Howren 2010   | +         | +       | +                  | +                  | +                  | ?                   |
| Howren 2013   | +         | +       | +                  | +                  | +                  | ?                   |
| Hsieh 2011    | --        | +       | +                  | +                  | +                  | ?                   |
| Karvonen 2008 | +         | +       | +                  | +                  | +                  | ?                   |
| Kim 2015      | +/-       | +       | +                  | +                  | +                  | ?                   |
| Konski 2003   | +/-       | +       | +                  | ?                  | +                  | +                   |
| Lofth 2008    | +         | +       | +                  | +                  | +                  | +                   |
| Mell 2010     | +/-       | +       | +                  | +                  | +                  | +                   |
| Oskam 2010    | +/-       | +       | +                  | +                  | +                  | ?                   |
| Orthus 2013   | +         | +       | +                  | +                  | +                  | ?                   |
| Pedruzzi 2008 | +/-       | +       | +                  | +                  | +                  | +                   |
| Ronis 2008    | +         | +       | +                  | +                  | +                  | ?                   |
| Sadat 2012    | --        | +       | +                  | +                  | +                  | ?                   |
| Sanabria 2007 | +         | +       | +                  | +                  | +                  | ?                   |
| Shah 2012     | +/-       | +       | +                  | +                  | +                  | ?                   |
| Siddiqui 2008 | +/-       | +       | +                  | +                  | +                  | ?                   |
| Sze 2012      | +/-       | +       | +                  | +                  | +                  | ?                   |
| Tarisiano 2012 | --       | +       | +                  | +                  | +                  | ?                   |
| Urba 2012     | +/-       | +       | +                  | +                  | +                  | ?                   |
| Wang 2014     | +         | +       | +                  | +                  | +                  | ?                   |
| Weed 1995     | +/-       | +       | +                  | +                  | +                  | ?                   |
| Wong 2006     | +/-       | +       | +                  | +                  | +                  | ?                   |
Conclusion

Functional and cognitive impairment, depressive symptoms and social isolation are highly prevalent in head and neck cancer patients and associate with high risk of adverse health outcomes. In the future, these measurements may guide decision-making and customize treatments, but more research is needed to further improve and firmly establish clinical usability.

Conflict of interest

None declared.

Acknowledgements

We would like to thank Jan Schoones for his support in the database searches. The Institute for Evidence-based Medicine (IEMO) is funded by the Dutch Ministry of Health and Welfare and supported by ZonMw (project number 62700.3002).

Appendix A. Supplementary material

Supplementary data associated with this article can be found in the online version, at http://dx.doi.org/10.1016/j.oraloncology.2016.11.013.

References

[1] Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: burdens upon an aging, changing nation. J Clin Oncol: Off J Am Soc Clin Oncol 2009;27:2758–65.

[2] Pulte D, Brenner H. Changes in survival in head and neck cancers in the late 20th and early 21st century: a period analysis. Oncologist 2010;15:994–1001.

[3] Michiels S, Le Maitre A, Buyse M, Burzynkowski T, Maillard E, Bogaerts J, et al. Surrogate endpoints for overall survival in locally advanced head and neck cancer: meta-analyses of individual patient data. Lancet Oncol 2009;10:341–50.

[4] Hashibe M, Brennan P, Benhamou S, Castillejas X, Chen C, Curado MP, et al. Alcohol drinking in never users of tobacco, cigarette smoking in never drinkers, and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. J Natl Cancer Inst 2007;99:777–87.

[5] Franceschi S, Bidoli E, Negri E, Barbone F, La Vecchia C. Alcohol and cancers of the upper aerodigestive tract in men and women. Cancer Epidemiol Biomark Prev 1994;3:299–304 [A publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology].

[6] Anstey KJ, van Soelen C, Salim A, O’Kearney R. Smoking as a risk factor for dementia and cognitive decline: a meta-analysis of prospective studies. Am J Epidemiol 2007;166:376–87.

[7] North TL, Palmer TM, Lewis SJ, Cooper R, Power C, Pattie A, et al. Impact of smoking on physical and cognitive capability in later life: a multistage cohort study using observational and genetic approaches. BMJ Open 2015;5:e008393.

[8] Richards M, Jarvis MJ, Thompson N, Wadsworth ME. Cigarette smoking and cognitive decline in midlife: evidence from a prospective birth cohort study. Am J Public Health 2003;93:994–8.

[9] Boje CR. Impact of comorbidity on treatment outcome in head and neck squamous cell carcinoma - a systematic review. Radiother Oncol: J Eur Soc Ther Radiol Oncol 2014;130:81–90.

[10] Datema FR, Ferrier MB, Baatenburg de Jong RJ. Impact of severe malnutrition on postoperative complications, prolonged length of hospital stay, and short-term mortality in elderly patients with malignant head and neck neoplasm. ORL 2016;78:153–64 [J: Laryngologie et de chirurgie cervico-faciale 2015;44:38]

[11] Sanabria A, Carvalho AL, Vartanian JC, Magrin J, Ikeda MK, Kowalski LP. Comorbidity is a prognostic factor in elderly patients with head and neck cancer. Ann Surg Oncol 2007;14:1449–57.

[12] Hye HC, Ng WT, Chan OS, Shum TC, Chan LL, Lee AW. Radical radiotherapy for nasopharyngeal carcinoma in elderly patients: the importance of co-morbidity assessment. Oral Oncol 2012;48:162–7.

[13] Hall SF, Groome PA, Irish J, OSullivan B. Towards further understanding of prognostic factors for head and neck cancer patients: the example of hypopharyngeal cancer. Laryngoscope 2009;119:696–702.

[14] Hshey YY, Mu-Hsin Chang P, Chen MH, Chu PY, Tzeng CH, Chang SY, et al. Pretreatment risk stratification for non-metastatic head and neck squamous cell carcinoma in a high-prevalence area. J Chin Med Assoc: JCMA 2011;74:487–92.

[15] Mell LR, Dignam JJ, Salama JK, Cohen EE, Polite BN, Dandekar V, et al. Predictors of competing mortality in advanced head and neck cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2010;28:15–20.

[16] Urbis S, Gatz J, Shen W, Hossain A, Winfree K, Koustenis A, et al. Quality of life scores as prognostic factors of overall survival in advanced head and neck cancer: analysis of a phase III randomized trial of pemetrexed plus cisplatin versus monotherapy. Oral Oncol 2012;48:723–9.

[17] Wang JR, Habbous S, Espin-Garcia O, Chen D, Huang SH, Simpson C, et al. Comorbidity and performance status as independent prognostic factors in head and neck squamous cell carcinoma patients. Head Neck 2016;38:335–42.

[18] Fang FM, Liu YT, Tang Y, Wang CJ, Ko SF. Quality of life as a survival predictor for patients with advanced head and neck cancer treated with radiotherapy. Cancer 2004;100:425–32.

[19] de Graaff A, de Leeuw JR, Ros WJ, Hordijk GB, Blijhäm GH, Wijnbstat JA. Sociodemographic factors and quality of life as prognostic indicators in head and neck cancer. Eur J Cancer 2001;37:332–9.

[20] Konishi A, Berkeley BA, Kian AK, Fu KK. Effect of education level on outcome of patients treated on Radiation Therapy Oncology Group Protocol 90–03. Cancer 2003:98:1497–503.

[21] Lorfi CJ, Cavalcanti Rde C, Costa e Silva AM, Latorre Mdo R, Ribeiro Kde C, Carvalho AL, et al. Risk factors for surgical-infections in head and neck cancer surgery. Otolaryngol–Head Neck Surg: Off J Am Acad Otolaryngol-Head Neck Surg 2008;138:74–80.

[22] Sadat F, Wienke A, Dunst J, Kuhnth T. Survival of patients with head and neck cancer. Impact of physical status and comorbidities. Strahlentherapie und Onkologie: Organ der Deutschen Röntgengesellschaft 2012;188:62–70.

[23] Siddiqui F, Pajak TF, Watkins-Bruner D, Konisi AK, Coyne JC, Gwede CK, et al. Pretreatment quality of life predicts for locoregional control in head and neck cancer patients: a radiation therapy oncology group analysis. Int J Radiat Oncol Biol Phys 2008;70:535–60.

[24] Pedruzzi PA, Kowalski LP, Nishimoto IN, Oliveira BV, Tironi F, Ramos GH. Analysis of prognostic factors in patients with oropharyngeal squamous cell carcinoma treated with chemotherapy alone or in combination with systemic chemotherapy. Arch Otolaryngol–Head Neck Surg 2008;134:1196–204.

[25] Shah S, Weed HG, He X, Agrawal A, Ozer E, Schuller DE. Alcohol-related predictors of delirium after major head and neck cancer surgery. Arch Otolaryngol–Head Neck Surg 2012;138:266–71.

[26] Weed HG, Lutman CV, Young DC, Schuller DE. Preoperative identification of patients at risk for delirium after major head and neck cancer surgery. Laryngoscope 1995;105:1066–8.

[27] Kammerlid E, Slander E, Hornestam L, Sullivan M. Health-related quality of life three years after diagnosis of head and neck cancer–a longitudinal study. Head Neck 2001;23:113–25.

[28] Howren MB, Christensen AJ, Karnell LH, Funk GF. Health-related quality of life in head and neck cancer survivors: impact of pretreatment depressive symptoms. Health Psychol: Off J Div Health Psychol Am Psychol Assoc 2010;29:65–71.

[29] Konishi A, Dufour SA, Fowler KE, Khan MJ, Terrell JE. Changes in quality of life over 1 year in patients with head and neck cancer. Arch Otolaryngol–Head Neck Surg 2008;134:241–8.

[30] Barber B, Dergousoff J, Nesbitt M, Mitchell N, Harris J, O’Connell D, et al. Depression as a predictor of postoperative functional performance status (FUPF) and treatment adherence in head and neck cancer patients: a prospective study. J Otolaryngol – Head Neck Surg = Le Journal d’oto-rhino-laryngologie et de chirurgie cervico-faciale 2015;44:38.

[31] See IC, Aarstad AK, Heimdahl JH, Olufson J, Mood, anxiety and sense of humor in head and neck cancer patients in relation to disease stage, prognosis and quality of life. Acta Otolaryngol 2005;125:557–65.

[32] Karvonen-Gutierrez CA, Ronis DL, Fowler KE, Terrell JE, Gruber SB, Dufour SA. Quality of life scores predict survival among patients with head and neck cancer. J Clin Oncol: Off J Am Soc Clin Oncol 2008;26:2754–60.

[33] Kim SA, Roh JL, Lee SA, Lee SW, Kim SB, Choi SH, et al. Pretreatment depression as a prognostic indicator of survival and nutritional status in patients with head and neck cancer. Cancer 2016;122:131–40.

[34] Wells G, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis; 2012. www.ohri.ca/programs/clinical_epidemiology/oxford.asp.

[35] Cochrane MF, Dias FL, de Faria TF, Albuquerque Sousa B, Thuler LC. Predictors of postoperative complications, prolonged length of hospital stay, and short-term mortality in elderly patients with malignant head and neck neoplasm. ORL 2016;78:153–64 [J: Laryngologie et de chirurgie cervico-faciale 2015;44:38].
Osikam IM, Verdonck-de Leeuw IM, Aaronson NK, Kuik DJ, de Bree R, Doornaert P, et al. Quality of life as predictor of survival: a prospective study on patients treated with combined surgery and radiotherapy for advanced oral and oropharyngeal cancer. Radioter Oncol J Eur Soc Ther Radiol Oncol 2010;97:258–62.

Taristano A, Pizzigallo A, Ballone E, Marchetti C. Health-related quality of life as a survival predictor for patients with oral cancer: is quality of life associated with long-term overall survival? Oral Surg Oral Med Oral Pathol Oral Radiol 2012;114:756–63.

Wong YK, Tsai WC, Lin JC, Poon CK, Chao SY, Hsiao YL, et al. Socio-demographic factors in the prognosis of oral cancer patients. Oral Oncol 2006;42:993–906.

Osthus AA, Aarstad AK, Olofsson J, Aarstad HJ. Prediction of survival by pretreatment health-related quality-of-life scores in a prospective cohort of patients with head and neck squamous cell carcinoma. JAMA Otolaryngol–Head Neck Surg 2013;139:14–20.

Borggreven PA, Aaronson NK, Verdonck-de Leeuw IM, Muller MJ, Heiligers ML, Bre R, et al. Quality of life after surgical treatment for oral and oropharyngeal cancer: a prospective longitudinal assessment of patients reconstructed by a microvascular flap. Oral Oncol 2007;43:1034–42.

Howren MB, Christensen AJ, Hynds Karnelli L, Van Liew JR, Funk GF. Influence of pretreatment social support on health-related quality of life in head and neck cancer survivors: results from a prospective study. Head Neck 2013;35:779–87.

Epstein JB, Lunn R, Le ND, Stevenson-Moore P, Gorsky M. Patients with oropharyngeal cancer: a comparison of adults living independently and patients living in long-term care facilities. Spec Care Dentistry 2005;25:124–30 [Official publication of the American Association of Hospital Dentists, the Academy of Dentistry for the Handicapped, and the American Society for Geriatric Dentistry].

National Cancer Institute. Surveillance, epidemiology, and end results program. Available at http://www.seer.cancer.gov [accessed March 30, 2016].

Broekhuizen K, Pothof A, de Craen AJ, Mooijaart SP. Characteristics of randomized controlled trials designed for elderly: a systematic review. PLoS One 2015;10:e0126709.

Mooijaart SP, Broekhuizen K, Trompet S, de Craen AJ, Gusseklooj J, Oleksik A, et al. Evidence-based medicine in older patients: how can we do better? Neth J Med 2015;73:211–8.

Scott JA, Guyatt GH. Cautionary tales in the interpretation of clinical studies involving older persons. Arch Intern Med 2010;170:587–95.

van de Water W, Bastiaannet E, Hille ET, Meershoek-Klein Krabbeeng EM, Putter H, Seynaeve CM, et al. Age-specific nonpersistence of endocrine therapy in postmenopausal patients diagnosed with hormone receptor–positive breast cancer: a TEAM study analysis. Oncologist 2012;17:55–63.

Feng MA, McMillan DT, Crowell K, Muss H, Nielsen ME, Smith AB. Geriatric assessment in surgical oncology: a systematic review. J Surg Res 2015;193:265–72.

Kristjansson SR, Neshakken A, Jordhov MS, Skovlund E, Audisio RA, Johanssens HO, et al. Comprehensive geriatric assessment can predict complications in elderly patients after elective surgery for colorectal cancer: a prospective observational cohort study. Crit Rev Oncol Hematol 2010;76:208–17.

Klepin HD, Geiger AM, Tooze JA, Newman AB, Colvert LH, Bauer DC, et al. Physical performance and subsequent disability and survival in older adults with malignancy: results from the health, aging and body composition study. J Am Geriatr Soc 2010;58:76–82.

Stedenski S, Perera S, Patel K, Rosano C, Faulkner K, Inzitari M, et al. Gait speed and survival in older adults. JAMA 2011;305:50–8.

Fish S, Byhardt RW, Gore E. Comorbidity and Karnofsky performance score are independent prognostic factors in stage III non-small-cell lung cancer: an institutional analysis of patients treated on four RTOG studies. Radiation Therapy Oncology Group. Int J Radiat Oncol Biol Phys 2002;54:357–64.

Kanesvaran R, Li H, Xiao KN, Poon D. Analysis of prognostic factors of comprehensive geriatric assessment and development of a clinical scoring system in elderly Asian patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 2011;29:3620–7.

Dasgupta M, Dumbrell AC. Preoperative risk assessment for delirium after noncardiac surgery: a systematic review. J Am Geriatr Soc 2006;54:1578–89.

Oresanya LB, Lyons WL, Finlayson E. Preoperative assessment of the older patient: a narrative review. JAMA 2014;311:2110–20.

Neuman HB, O’Connor ES, Weiss J, Loconte NK, Greenblatt DY, Greenberg CC, et al. Surgical treatment of colon cancer in patients aged 80 years and older: analysis of 31,574 patients in the SEER-Medicare database. Cancer 2013;119:639–47.

Pincus M, Duberstein PR. Depression and cancer mortality: a meta-analysis. Psychol Med 2010;40:1977–810.

Satir JR, Linden W, Phillips MJ. Depression as a predictor of disease progression and mortality in cancer patients: a meta-analysis. Cancer 2009;115:5349–61.

Goodwin JS, Hunt WC, Key CR, Samet JM. The effect of marital status on stage, treatment, and survival of cancer patients. JAMA 1987;258:3125–30.

Seeman TE, Berkman LF, Kohout L, Cralor A, Glynn R, Blazer D. Intercommunity variations in the association between social ties and mortality in the elderly. A comparative analysis of three communities. Ann Epidemiol 2003;13:325–35.

Famoujdjan F, Paillaud E, Zelek L, Laurent M, Levy V, Landre T, et al. Measurement of gait speed in older adults to identify complications associated with frailty: a systematic review. J Geriatr Oncol 2015;6:484–96.

Cesari M, Cerullo F, Zamboni V, Di Palmi R, Scambia G, Balducci L, et al. Functional status and mortality in older women with gynecological cancer. J Gerontol Ser A Biol Sci Med Sci 2013;68:1129–33.

Ferrat E, Paillaud E, Laurent M, Le Thuaut C, Caillet P, Tournigand C, et al. Predictors of 1-year mortality in a prospective cohort of elderly patients with cancer. J Gerontol A Biol Sci Med Sci 2015;70(9):1148–55.

Soubeyran P, Fonck M, Blanc-Bisson C, Blanc JF, Ceccaldi J, Mertens C, et al. Predictors of early death risk in older patients treated with first-line chemotherapy for cancer. J Clin Oncol Off J Am Soc Clin Oncol 2012;30:1829–34.

Handforth C, Clegg A, Young C, Simpkins S, Seymour MT, Selby PJ, et al. The prevalence and outcomes of frailty in older cancer patients: a systematic review. Ann Oncol 2015;26(6):1091–101.